

Tislelizumab RATIONALE 303

**PRELIMINARY SCORE**

**CURATIVE**



**NON-CURATIVE**



**ADJUSTMENTS**

**Quality of life**



QoL data pending



**Serious and disabling adverse effects**



**Other adjustments**



Tislelizumab RATIONALE 303

**FINAL SCORE**

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Thoracic Malignancies

Therapeutic Indication: Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab.

Experimental Arm: Tislelizumab

Control Arm: Docetaxel



